

High response seen for chemo in seniors with high-risk AML

June 20 2019



(HealthDay)—A substantial proportion of older patients with high-risk

acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in *Cancer Medicine*.

Sarah Bertoli, M.D., Ph.D., from the Centre Hospitalier Universitaire de Toulouse in France, and colleagues conducted a retrospective analysis to assess the characteristics and outcome of [patients](#) aged 60 to 75 years with secondary or therapy-related AML. A total of 218 patients fulfilled the liposomal encapsulation of cytarabine and daunorubicin (CPX-351) study criteria; of these, 83 percent received antileukemic treatment with [intensive chemotherapy](#) (121 patients) or hypomethylating agents (HMA; 60 patients).

The researchers found that the complete response rate was 69 percent for chemotherapy-treated patients and median overall survival was 11 months. Three- and five-year overall survival rates were 21 and 17 percent, respectively. The complete response rate was 15 percent for HMA-treated patients, while median overall survival was 11 months; the three- and five-year overall survival rates were 15 and 2 percent, respectively.

"These results compare favorably with the control [chemotherapy](#) arm of the CPX-351 trial which consisted of three daily doses of daunorubicin 60 mg/m² and seven daily doses of cytarabine 100 mg/m²," the authors write. "This schema is considered as the standard of care according to current guidelines."

Several authors disclosed financial ties to the [pharmaceutical industry](#).

More information: [Abstract/Full Text](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: High response seen for chemo in seniors with high-risk AML (2019, June 20) retrieved 6 May 2024 from

<https://medicalxpress.com/news/2019-06-high-response-chemo-seniors-high-risk.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.